Annual Financials for ALX Oncology Holdings Inc.
Operating Activities
Fiscal year is January-December. All values USD millions. |
| 2018 | 2019 | 2020 | 2021 |
5-year trend |
Net Income before Extraordinaries |
- | (13.73M) | (19.24M) | (45.74M) | (83.46M) | |
Net Income Growth |
- | - | -40.14% | -137.70% | -82.47% | |
Depreciation, Depletion & Amortization |
- | 431,000 | 429,000 | 202,000 | 736,000 | |
Depreciation and Depletion |
- | 431,000 | 429,000 | 202,000 | 736,000 | |
Amortization of Intangible Assets |
- | - | - | - | - | |
Deferred Taxes & Investment Tax Credit |
- | - | - | - | - | |
Deferred Taxes |
- | - | - | - | - | |
Investment Tax Credit |
- | - | - | - | - | |
Other Funds |
- | 269,000 | 308,000 | 7M | 18.65M | |
Funds from Operations |
- | (13.03M) | (18.51M) | (38.54M) | (64.07M) | |
Extraordinaries |
- | - | - | - | - | |
Changes in Working Capital |
- | (159,000) | 4.26M | 247,000 | (4.03M) | |
Receivables |
- | (932,000) | 396,000 | 536,000 | - | |
Accounts Payable |
- | (269,000) | 2.98M | (3.74M) | 3.29M | |
Other Assets/Liabilities |
- | 1.03M | 751,000 | (1.53M) | (10.62M) | |
Net Operating Cash Flow |
- | (13.19M) | (14.25M) | (38.29M) | (68.1M) | |
Net Operating Cash Flow Growth |
- | - | -8.03% | -168.71% | -77.86% | |
Net Operating Cash Flow / Sales |
- | -638.12% | -297.10% | -3,239.34% | - | |
Investing Activities
|
| 2018 | 2019 | 2020 | 2021 |
5-year trend |
Capital Expenditures |
- | (653,000) | (353,000) | (31,000) | (666,000) | |
Capital Expenditures (Fixed Assets) |
- | (653,000) | (353,000) | (31,000) | (666,000) | |
Capital Expenditures (Other Assets) |
- | - | - | - | - | |
Capital Expenditures Growth |
- | - | 45.94% | 91.22% | -2,048.39% | |
Capital Expenditures / Sales |
- | -31.59% | -7.36% | -2.62% | - | |
Net Assets from Acquisitions |
- | - | - | - | - | |
Sale of Fixed Assets & Businesses |
- | - | - | 641,000 | - | |
Purchase/Sale of Investments |
- | - | - | - | - | |
Purchase of Investments |
- | - | - | - | - | |
Sale/Maturity of Investments |
- | - | - | - | - | |
Other Uses |
- | - | - | - | (4.26M) | |
Other Sources |
- | - | - | - | - | |
Net Investing Cash Flow |
- | (653,000) | (353,000) | 610,000 | (4.92M) | |
Net Investing Cash Flow Growth |
- | - | 45.94% | 272.80% | -907.05% | |
Net Investing Cash Flow / Sales |
- | -31.59% | -7.36% | 51.61% | - | |
Financing Activities
|
| 2018 | 2019 | 2020 | 2021 |
5-year trend |
Cash Dividends Paid - Total |
- | - | - | - | - | |
Common Dividends |
- | - | - | - | - | |
Preferred Dividends |
- | - | - | - | - | |
Change in Capital Stock |
- | 1,000 | 2.61M | 469.39M | 2.75M | |
Repurchase of Common & Preferred Stk. |
- | (6,000) | - | - | - | |
Sale of Common & Preferred Stock |
- | 7,000 | 2.61M | 469.39M | 2.75M | |
Proceeds from Stock Options |
- | 7,000 | 2.61M | 469.09M | 202,000 | |
Other Proceeds from Sale of Stock |
- | - | - | 299,000 | 2.55M | |
Issuance/Reduction of Debt, Net |
- | - | - | (6.51M) | (281,000) | |
Change in Current Debt |
- | - | - | - | - | |
Change in Long-Term Debt |
- | - | - | (6.51M) | - | |
Issuance of Long-Term Debt |
- | - | - | - | - | |
Reduction in Long-Term Debt |
- | - | - | (6.51M) | (281,000) | |
Other Funds |
- | - | 12.75M | - | - | |
Other Uses |
- | - | - | - | - | |
Other Sources |
- | - | 12.75M | - | - | |
Net Financing Cash Flow |
- | 1,000 | 15.36M | 462.88M | 2.47M | |
Net Financing Cash Flow Growth |
- | - | 1,535,600.00% | 2,914.14% | -99.47% | |
Net Financing Cash Flow / Sales |
- | 0.05% | 320.20% | 39,160.83% | - | |
Exchange Rate Effect |
- | - | - | - | - | |
Miscellaneous Funds |
- | - | - | - | - | |
Net Change in Cash |
- | (13.84M) | 755,000 | 425.2M | (70.55M) | |
Free Cash Flow |
- | (13.84M) | (14.6M) | (38.32M) | (68.77M) | |
Free Cash Flow Growth |
- | - | -5.48% | -162.43% | -79.45% | |
Free Cash Flow Yield |
- | - | - | - | -7.94% | NA |